Murray also discusses the low-grade upper tract urothelial cancer treatment mitomycin-containing reverse thermal gel (Jelmyto).
In this video, Katie Murray, DO, explains what makes low-grade upper tract urothelial cancer difficult to treat and also discusses mitomycin-containing reverse thermal gel (Jelmyto). Murray is an assistant professor of surgery-urology at the University of Missouri, Columbia.
Lenvatinib/pembrolizumab compares favorably with frontline standards in renal cell carcinoma
February 2nd 2024“Combination therapy with lenvatinib plus pembrolizumab provides a comparable OS, and a trend of improvement in PFS and response outcomes, compared with most current global SOC therapies for treatment-naïve patients with advanced renal cell carcinoma,” the study authors wrote.
First-line pembrolizumab/lenvatinib shows efficacy for advanced non–clear cell RCC
January 29th 2024“Updated efficacy and safety results continue to support pembrolizumab plus lenvatinib as a first-line treatment option for patients with advanced non–clear cell RCC,” lead study author Martin H. Voss, MD.